---
title: "Honz: Expected loss of 168 million to 238 million yuan in 2025"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274294514.md"
description: "Honz expects a net loss attributable to shareholders of the listed company of RMB 168 million to RMB 238 million for the fiscal year 2025, an improvement compared to the net loss of RMB 216 million in the same period last year. The net loss after deducting non-recurring gains and losses is expected to be RMB 153 million to RMB 216 million. The company has increased its sales and R&D investment amid intense market competition, resulting in total operating costs exceeding total operating revenue"
datetime: "2026-01-30T10:52:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274294514.md)
  - [en](https://longbridge.com/en/news/274294514.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274294514.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274294514.md) | [English](https://longbridge.com/en/news/274294514.md)


# Honz: Expected loss of 168 million to 238 million yuan in 2025

Honz announced that it expects a net loss attributable to shareholders of the listed company for the fiscal year 2025 to be between 168 million yuan and 238 million yuan, compared to a loss of 216 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is expected to be between 153 million yuan and 216 million yuan, compared to a loss of 213 million yuan in the same period last year. During the reporting period, in the context of intensified competition in the pharmaceutical terminal market, the company continued to increase sales investment to enhance market share and expand marketing channels, as well as maintain long-term investment in research and development to cope with market competition, resulting in total operating costs exceeding total operating revenue despite little short-term change in operating income

### 相關股票

- [Honz (300086.CN)](https://longbridge.com/zh-HK/quote/300086.CN.md)

## 相關資訊與研究

- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/zh-HK/news/281570860.md)
- [Legrand SA (ENXTPA:LR) acquired TES Power Ltd.](https://longbridge.com/zh-HK/news/281361518.md)
- [Everus Acquires SE&M, Leading Contractor in Southeast Region | ECG Stock News](https://longbridge.com/zh-HK/news/281521912.md)
- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/zh-HK/news/281213207.md)
- [Miraval Resorts & Spas and Humin Set New Standard for the Future of Measurable Wellness with Groundbreaking New Study | H Stock News](https://longbridge.com/zh-HK/news/281216315.md)